(1) Receive any clinical trial drug treatment for COVID-2019 within 30 days before the screening assessment, (2) Severe liver disease (e.g., Child Pugh score >=C or AST> 5 times of the upper limit), (3) Patients with known severe renal insufficiency (estimated glomerular filtration rate <=30mL / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis, (4) Co-infection of HIV, hepatitis B, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses, (5) Female patients who have no sexual protection in the last 30 days prior to the screening assessment, (6) Pregnant or lactating women or women using estrogen contraception, (7) Patients who are planning to become pregnant during the study period or within 6 months after the end of the study period, (8) Other conditions that the researchers consider inappropriate for participating in this clinical trial.

(1) Receive any clinical trial drug treatment for COVID-2019 within 30 days before the screening assessment, (2) Severe liver disease (e.g., Child Pugh score >=C or AST> 5 times of the upper limit), (3) Patients with known severe renal insufficiency (estimated glomerular filtration rate <=30mL / min/1.73 m2) or patients receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis, (4) Co-infection of HIV, hepatitis B, tuberculosis, influenza virus, adenovirus or other respiratory infection viruses, (5) Female patients who have no sexual protection in the last 30 days prior to the screening assessment, (6) Pregnant or lactating women or women using estrogen contraception, (7) Patients who are planning to become pregnant during the study period or within 6 months after the end of the study period, (8) Other conditions that the researchers consider inappropriate for participating in this clinical trial.